Abstract Library

#4523 Preoperative evaluation of tumour border using radiomics and its surgical guidance in pancreatic neuroendocrine tumours

Introduction: Pancreatic neuroendocrine tumours are a heterogeneous group of tumours originating from peptidergic neurons and neuroendocrine cells with variable survival outcomes. Surgical resection is the mainstay of treatment. However, there is an ambiguous insight into the real need to execute the standard surgery in small pancreatic neuroendocrine tumours. The tumour border is a powerful determinant of survival prognosis in many tumours and is often used as a safety guarantee for parenchyma-sparing resections. However, there are no studies evaluating tumour border with or without preoperative imaging in pNETs.

Conference:

Presenting Author: Wang Y

Authors: Wang Y, Gu W, Tang W, Huang D, Zhang W,

Keywords: pancreatic neuroendocrine tumour, border, computed tomography, enucleation, radiomics,

#4513 Predictive value of different PD-L1 immunohistochemistry clones for immunotherapy efficacy in neuroendocrine tumours: A case series

Introduction: In the ZS001 clinical trial, we observed that NET patients with higher PD-L1 expression levels were more likely to benefit preferentially from immunotherapy.

Conference:

Presenting Author:

Authors: Sun Y, Zhang Q, Cao F, Huang X, Zhang P,

Keywords: neuroendocrine tumour, immunotherapy, PD-L1, SP142, 28-8, C0148, E1L3N,

#4509 Epidemiological characteristics and prognosis analysis of gastric cancer (GC) with neuroendocrine differentiation (NED)

Introduction: GC with NED exhibits distinct biological characteristics, yet research on its clinical features and prognosis remains limited.

Conference:

Presenting Author: Zhang J

Authors: Huang Z, Li J, Wang C, Shen Y, Rao S,

Keywords: gastric cancer, neuroendocrine differentiation, Epidemiological characteristics, prognosis,

#4501 Efficacy and safety of surufatinib in unresectable or metastatic grade 3 neuroendocrine tumours (NET G3): A national multi-centre, retrospective study

Introduction: Currently, there are limited treatment options for NET G3 and therapeutics for NET G1/2 may be considered as alternatives.

Conference:

Presenting Author: Hao J

Authors: Wang J, Zhang N, Liang Y, Long J, Chi Y,

Keywords: surufatinib, NET G3,

#4473 Somatostatin analogue delayed the recrudescence of stomach NET: A real-world study

Introduction: Type 1 gastric NENs (g-NENs) are common and relapse easily. Somstostatin analogues (SSAs) can inhibit gastrin secretion and cell proliferation. While the usage of SSAs in g-NENs is still controversial.

Conference:

Presenting Author: Cai W

Authors: Cai W, Zhang J, Ge W, Hu H,

Keywords: somatostatin analogue, Type 1 gastric NEN, real-world study,